Cabozantinib plus nivolumab and ipilimumab in renal cell carcinoma
Author:
Affiliation:
1. Department of Medical Oncology, Dr. B.R.A. Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi, India
Publisher
Medknow
Subject
Cancer Research,Oncology (nursing),Drug Guides,Oncology
Reference7 articles.
1. Cabozantinib plus nivolumab and ipilimumab in renal-cell carcinoma;Choueiri;N Engl J Med,2023
2. Ipilimumab and nivolumab (I+N) as first-line treatment of metastatic renal cell carcinoma (mRCC): A real-world review in Northwest of England, United Kingdom;Allison;J Clin Oncol,2021
3. Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma;Choueiri;N Engl J Med,2021
4. Activity of cabozantinib after immune checkpoint blockade in metastatic clear-cell renal cell carcinoma;McGregor;Eur J Cancer,2020
5. Nivolumab plus ipilimumab plus cabozantinib triplet combination for patients with previously untreated advanced renal cell carcinoma: Results from a discontinued arm of the phase III CheckMate 9ER trial;Apolo;Eur J Cancer,2022
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3